Catalyst Clinical Research

Catalyst concentrates on oncology and rare disease clinical trials. These are areas where trial complexity, site identification, and patient recruitment require dedicated operational expertise rather than a generalist CRO approach. The firm's oncology work covers both solid tumors and hematologic malignancies.

No. Catalyst established a European subsidiary, Catalyst Clinical Research Europe, to support multi-regional trials. This allows the firm to manage studies requiring parallel compliance with both FDA and European Medicines Agency regulatory pathways, which is common in oncology drug development.

Under the functional service provider model, sponsors can contract for specific capabilities — such as clinical monitoring, biostatistics, or data management — without handing over the entire trial program. This appeals to biotech companies that employ internal medical directors and prefer to retain program-level oversight while outsourcing specific operational functions.

The firm competes in the mid-tier CRO segment against other oncology-focused providers. The Durham, North Carolina area is also home to IQVIA, the largest global CRO, and formerly Syneos Health. Catalyst differentiates by remaining therapeutically concentrated rather than pursuing the broad-indication strategy of its larger neighbors.

Yes. The company was recognized on the Inc. 5000 list of fastest-growing private US companies in 2020. The CRO sector broadly benefited from increased pharmaceutical R&D outsourcing during this period, and mid-tier specialists like Catalyst captured market share from larger, less therapeutically-focused incumbents.